Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib
about
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells.Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
P2860
Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib
@ast
Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib
@en
type
label
Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib
@ast
Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib
@en
prefLabel
Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib
@ast
Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib
@en
P2860
P1476
Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib
@en
P2093
Catherine J Wu
Pavan Bachireddy
P2860
P304
P356
10.1158/1078-0432.CCR-15-3106
P407
P577
2016-02-04T00:00:00Z